More at link
By Ransdell Pierson
1 hour, 15 minutes ago
NEW YORK (Reuters) - An experimental Merck & Co. Inc. (NYSE:MRK - news) vaccine completely prevented early-stage cervical cancer and precancerous cervical lesions caused by the two most common forms of a virus linked to such cancers, Merck said on Thursday.
This trial confirms that a vaccine can give young women a high level of protection from developing precancerous lesions and early cervical cancers," Laura Koutsky, a professor of epidemiology at the University of Washington, who led the study, told Reuters.
The ability to prevent onset of cervical cancers, at least for the short term, was shown in a late-stage trial sponsored by the U.S. drug maker. It included more than 12,000 women from 13 countries, aged 16 to 26, who were not infected with either of the virus types when the trial began
By Ransdell Pierson
1 hour, 15 minutes ago
NEW YORK (Reuters) - An experimental Merck & Co. Inc. (NYSE:MRK - news) vaccine completely prevented early-stage cervical cancer and precancerous cervical lesions caused by the two most common forms of a virus linked to such cancers, Merck said on Thursday.
This trial confirms that a vaccine can give young women a high level of protection from developing precancerous lesions and early cervical cancers," Laura Koutsky, a professor of epidemiology at the University of Washington, who led the study, told Reuters.
The ability to prevent onset of cervical cancers, at least for the short term, was shown in a late-stage trial sponsored by the U.S. drug maker. It included more than 12,000 women from 13 countries, aged 16 to 26, who were not infected with either of the virus types when the trial began